Even if we accept this dictum of historian-philosopher Will Durant, we must face a troubling question: How much of the nation's wealth can we afford to devote to the nation's health? It is a question that assumes increased importance when we consider the percentage of the gross national product (GNP) allocated to medical care over the period from 1955 to the present. In 1955 the United States devoted only 4.4% of its GNP to health care, and as late as 1965 health care costs comprised a relatively modest 6.0% of the GNP.2 However, by 1975 the figure was 8.6%2 and in 1983 the nation spent 10.8%3 of its GNP on health care. Moreover, there is reason to believe that the proportion of GNP absorbed by medical care costs will continue to increase. Between 1981 and 1982, medical costs increased at approximately twice the general rate of inflation.4
Even if we accept this dictum of historian-philosopher Will Durant, we must face a troubling question: How much of the nation's wealth can we afford to devote to the nation's health? It is a question that assumes increased importance when we consider the percentage of the gross national product (GNP) allocated to medical care over the period from 1955 to the present. In 1955 the United States devoted only 4.4% of its GNP to health care, and as late as 1965 health care costs comprised a relatively modest 6.0% of the GNP.2 However, by 1975 the figure was 8.6%2 and in 1983 the nation spent 10 .8%3 of its GNP on health care. Moreover, there is reason to believe that the proportion of GNP absorbed by medical care costs will continue to increase. Between 1981 and 1982, medical costs increased at approximately twice the general rate of inflation. 4 The increasing costs of medical care are, in one economist's view, attributable to the successes of medical research coupled with the expansion of medical insurance coverage .5 A recently released survey6 indicates that the advances in medical treatments and equipment are widely viewed as the main reason for escalating medical costs. The survey included national samples from the six following groups: a cross section of the public (adults); physicians heading local, state, and specialty medical societies; administrators from the nation's largest hospitals; senior health insurance executives; corporate benefit officers; and trade union leaders responsible for health care benefits. Participants were presented with three alternatives and asked to identify the one that they believed to be the main reason for increased spending on health care services. The alternatives were phrased as follows: (1) the increasing cost of the same services, (2) the use of new and more expensive treatments and equipment, and (3) people using more health care services than they used to. According to data published by the Health Care Financing Administration (HCFA),2 the correct response is clearly the first of the three alternatives. Increased costs for the same medical goods and services accounted for 78% of the increase in personal health care expenditures between 1981 and 1982. With another 8% of the increase accounted for by population growth, only 14% of the increase could be attributed to such other factors as the aging of the population and changes in the nature and quantity of services rendered. Figure 1 suggests that the survey respondents were not generally familiar with the HCFA analysis. The use of new and more expensive treatments and equipment was the most frequently cited reason among physician leaders, hospital administrators, and insurance executives, and the second most frequently cited reason by the public cross section, corporate benefit officers, and union leaders.
It is important to note that in selecting the alternative relating to medical treatments and equipment, the respondents not only evinced an unfounded belief that advances in medical technology are the primary source of escalating medical costs, but also implicitly accepted the concept that new medical treatments and equipment are necessarily more expensive. This implication warrants examination since there are instances in which advances in research and technology actually lead to reduced costs. In performing our examination, we will first draw on the wisdom of Lewis Thomas, who in The Lives ofa Cell discussed the cost-effectiveness of three levels of "technology of medicine."7 We will then consider a number of advances in the treatment of heart diseases in the context of economist Burton Weisbrod's graphic representation of the historical relationship between health expenditures and the state of medical technology (figure 2).
As used by Dr. Thomas is sometimes called supportive therapy because it tides the patient over diseases that, by and large, are not understood. "High technology" makes it possible to treat diseases successfully (e.g., antibiotics) or to prevent them (e.g., immunizations). It is based on a genuine understanding of the disease mechanism and when it becomes available it is likely to be relatively inexpensive and easy to deliver. "Halfway technology" represents the kinds of things that must be done to compensate for the incapacitating effects of disease or to postpone death and is likely to be both complex and costly. According to Dr. Thomas, it is the appropriate characterization for most of the presently available treatments for heart disease. As indicated by the Weisbrod curve (figure 2), the introduction of new halfway technologies may either increase or decrease medical treatment costs. In the following discussion we will explore the cost implications of several halfway technologies for heart disease.
Treatment for coronary artery disease. The most wellknown and widely practiced halfway technology for coronary artery disease is the coronary artery bypass graft (CABG) procedure. The number of procedures performed in the United States is estimated to have increased from 20,000 in 1971 to 50,000 in 1974, 70,000 in 1977,8 and 191,000 in 1983.* The rapid rate of increase in bypasses is not surprising given the marked relief from angina obtainable with CABG at relatively low operative risk. As a result of its widespread adoption, CABG alone is estimated to have accounted for approximately 1 % of the nation's annual health care costs in 1980. minal coronary angioplasty (PTCA), an altemative operative procedure for some potential CABG patients. As indicated in figure 3 , both medical treatment and PICA are associated with lower treatment costs than CABG. Therefore, a showing that either medical treatment or PTCA is equal to CABG in effectiveness for any substantial percentage of patients eligible for CABG would necessarily result in substantial cost savings.
The question of comparative effectiveness of medical and surgical treatment in selected patients was addressed in the recently reported Coronary Artery Surgery Study (CASS) supported by the National Heart, Lung, and Blood Institute. The study consisted of both a registry of patients undergoing diagnostic coronary arteriography and a randomized trial of surgical vs medical treatment among registry patients for whom the best therapeutic choice was a matter of physician judgment and patient preference rather than generally accepted practice. At the end of 5 years, the trial results`0 showed no statistically significant differences in average mortality between medically and surgically assigned patients either overall or when separated according to whether they had single-, double-, or triplevessel disease. An additional 15 months of follow-up altered the initial CASS results for only those patients with triple-vessel disease and ejection fractions below 0.50."1 An apparent mortality advantage associated with surgery in such patients was suggested in the initial results but became statistically significant only after further follow-up. The showed that at the end of 5 years, less than one-quarter of the medically assigned patients had "crossed" to surgical therapy, with most of the crossover resulting from worsening angina despite vigorous medical therapy. The excellent survival observed in both the medically and surgically assigned CASS patients and the similarity of survival rates in groups of patients assigned to the two therapies suggests that patients similar to those who particiated in CASS, i.e., patients with mild-to-moderate angina and angina-free survivors of myocardial infarction with surgically approachable coronary artery disease, who do not have both triple-vessel disease and ejection fractions below 0.50 can safely defer bypass surgery until worsening symptoms require surgical palliation. The cost-saving implications of CASS are threefold. First, surgical costs were not incurred for three-fourths of the medically assigned patients during the 5 years of the study. Second, after entry into the trial, the medically assigned patients experienced fewer incidents of hospitalization and averaged 5 fewer days of hospitalization than those in the surgically assigned group.12 Therefore, for the medically assigned patients there were savings in direct costs because the surgery was not performed and because they required fewer days of hospitalization. Finally, there were savings in indirect costs among the medically assigned patients in that they lost fewer days of employment due to hospitalization.
An estimated 508,000 coronary angiographic procedures were performed in 1983. * Extrapolating from the CASS data, an estimated 64,500 (12.7%) of the patients undergoing these procedures would have been eligible for randomization into surgical or medical groups, and approximately 27,735 (43%) of them would have undergone coronary bypass surgery. Since patients with triple-vessel disease and ejection fractions below 50% comprised 10% of the randomized patients, it is reasonable to conclude that all but 2774 of the 27,735 bypass procedures could have been deferred without jeopardizing any lives. Assuming the cost of bypass surgery to be $20,000,t the estimated cost savings associated with foregoing approximately 25,000 bypass procedures would be on the order of $500 million. It should be noted, however, that in the course of each year about 5% of the medically assigned patients in the trial elected to undergo bypass surgery because of worsening symptoms. 
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As indicated in figure 3, PTCA offers another lower-cost alternative to CABG in selected cases. Because the PTCA procedure can be performed in cardiac catheterization laboratories, patients do not incur hospitalization costs. In a recent study conducted at 11 centers among patients with single-vessel disease, the mean success rate for PTCA was 80%. 1 ' Bypass surgery was performed on each of the patients in whom PTCA was unsuccessful. Estimates of the comparative direct costs of PTCA and CABG are available from the study. The direct costs per case for 206 patients undergoing PTCA averaged $5315, compared with $15,580 per case for 195 patients undergoing the CABG procedure. Allowing for the costs of surgery and hospitalization among the 20% who required bypass graft after PTCA, the total cost per case for PTCA was $7149. Assuming that the number of patients with single-vessel disease who receive PTCA instead of CABG each year is between 17,000 and 25,000, the annual direct cost savings would be between $122 and $179 million. Sizeable savings can also be expected in indirect costs because 79% of the patients who underwent PTCA returned to work compared with 69% of those who underwent CABG. Moreover, the average time elapsed before returning to work was only 3 weeks for the former compared with 11 weeks for the latter patients. 14 Cardiac pacemakers. The pacemaker appears to be an example of a halfway technology with increasing cost per case. The new dual-chamber, multiprogrammable models cost on the order of $5000, compared with the $2500 unit cost for the most commonly used singlechamber models. 5 In addition, dual-chamber units are not as long-lived as single-chamber units so that greater operative costs are associated with dual-chamber implants.
There are indications that the dual-chamber technology is beginning to be widely adopted. A Opinions differ widely on the percentage of the permanent pacemaker population for whom a dual-chamber device is indicated. Table 1 lists a number of published estimates of the appropriate percentage of dual-chamber implants along with the corresponding incremental costs that each would entail when compared with the 1978 rate for atrial-lead implants.
Heart replacement. By far the most costly halfway technologies developed in recent years have been those relating to replacement of the irreparably damaged heart. Despite its great expense and the limited availability of donor hearts, transplantations have been effective for some patients. Public attention has recently focused on the artificial heart because of the relatively successful experience with Dr. Barney Clark. At the NHLBI current programs have been emphasizing the development of a circulatory assist device to sustain prospective transplant recipients pending the procurement of a satisfactory replacement organ. It is clear that the costs associated with transplants that are preceded by circulatory assist implants will substantially exceed those of transplants alone.
The project director for the National Heart Transplantation Study sponsored by the HCFA estimated a 1980 cost of $177,600 to perform a transplant and then maintain the recipient for 1 year.18 A potential transplant recipient who first received an artificial assist device would incur all of the costs included in the transplant estimate along with the additional operative costs for a second implantation procedure. Allowing the $120,000 reported as the total operative cost for a transplant, a reasonable estimate of the total cost for a 100,000 1964 1966 1968 1970 1972 1974 1976 * 1978 1980 1962 temporary circulatory assist device implant followed by a transplant would be $297,600. Over the years the program to develop an artificial heart has engendered considerable comment, the most frequently expressed concern being that there will be wide demand for access to a successful device. Despite the attention directed toward the artificial heart program, the Institute's support for the program has remained relatively constant in absolute dollars ( figure  4 ). When adjusted for inflation, there has been an actual decline in the level of support. The total NHLBI commitment for the program from its inception in fiscal year 1964 through fiscal year 1982 has been approximately $161.5 million. The returns on the NHLBI investment include a number of major contributions to the treatment of heart disease as well as results that have proved to be beneficial outside the area of heart disease.
Research for the artificial heart program led to the development of the heart-lung machine, the device that permitted a total of 84,000 open heart operations and 191,000 bypass procedures to be performed in 1983.* The program also led to the development of the intraaortic balloon that provides circulatory assistance to patients recovering from corrective heart surgery. Results of biomaterials research sponsored by the program have found applications in areas ranging from replacement heart valves to airplane windshields. It is likely that such advances would not now be available if the program had been abandoned over concern about the cost and extensive demand for its end product. When compared with the overall NHLBI appropriations in fiscal years 1964 through 1982, it is clear that the, artificial heart program never absorbed a major portion of NHLBI resources and since fiscal year 1967 tended to receive an ever-decreasing share of those 
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While the applied research of the artificial heart program continued, the basic research supported by the NHLBI added further to our understanding of the underlying processes of atheroslerosis and the risk factors associated with the development of heart disease. It is not unreasonable to expect that the product of our basic research efforts will be the most effective control on the demand for the ultimate end product of the artificial heart program.
Summary. We have discussed some of the new halfway technologies in cardiology and showed how they differ markedly in their relative effects on overall patient treatment costs. We have tried to present a balanced picture by providing examples in which advances in cardiology offer clear reductions in medical care costs, while acknowledging the potential for increased costs due to other advances. The results of CASS and the development of PTCA indicate that there are lower-cost replacements for bypass surgery in selected patients. On the other hand, the new dualchamber pacemakers offer greater patient benefits but also carry an increase in unit cost. Use of the artificial heart as an interim measure in transplant candidates will expand the applicability of the existing transplant technology. We know that the overall patient treatment cost for transplants will increase dramatically if the use of two implantations in each patient becomes routine, and when coupled with the expanded availability of transplants, the resultant increase in total medical care costs could be substantial. The social benefits of expanded transplant capability remain speculative.
What we do know is that overall our national investment in heart research continues to provide dramatic returns. We need only look at the coincidence of research advances related to and the declining national mortality for cardiovascular disease to gain an appreciation of the benefit of our research commitment. In fact, while reductions in age-adjusted mortality are associated with increased medical care expenditures in general, substantially greater reductions are associated with increased expenditures for the treatment of cardiovascular disease. 19 We as a nation have clearly benefited from the continued increase in the percentage of the GNP devoted to the health care cost. Without discounting the importance of restraining further growth in medical care costs, we must keep in mind the nature of the medical care costs included in the GNP. They are only direct costs. The GNP does not attempt to capture the indirect costs of disease. According to Mushkin,20 the indirect costs of disease, including output loss due to sickness and the costs of premature death, comprised 90% of the total economic cost of disease in 1900 and 67% of that in 1975. Assuming that the existing trends in direct costs of disease continued, Mushkin estimated that it would not be until the year 2000 that the direct costs of disease would be approximately equal to the indirect costs. With a continued emphasis on basic research, we should soon be developing high technology approaches to cardiovascular disease that may not merely restrain the growth of direct costs of illness but actually serve to reduce the total economic costs of cardiovascular disease.
